Klotho Neurosciences, Inc. (KLTO)

NASDAQ: KLTO · Real-Time Price · USD
0.1820
-0.0095 (-4.96%)
At close: May 30, 2025, 4:00 PM
0.1816
-0.0004 (-0.22%)
After-hours: May 30, 2025, 7:54 PM EDT
-4.96%
Market Cap 5.91M
Revenue (ttm) n/a
Net Income (ttm) -7.71M
Shares Out 32.49M
EPS (ttm) -0.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 632,318
Open 0.1800
Previous Close 0.1915
Day's Range 0.1764 - 0.1900
52-Week Range 0.1135 - 0.9900
Beta 0.02
Analysts n/a
Price Target n/a
Earnings Date May 15, 2025

About KLTO

Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates comprise KLTO-101 for the treatment or prevention of Alzheimer’s disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig’s disease. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2019
Employees 3
Stock Exchange NASDAQ
Ticker Symbol KLTO
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

Klotho Neurosciences to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco

NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a specialty biotechnology company focused on developing cell and gene therapies for amyotrophic lateral sclerosis...

5 months ago - GlobeNewsWire

ANEW MEDICAL, INC. Secures Key Patent in Europe for Human Klotho Gene RNA Slice Variant and Protein

ANEW to explore therapeutics and specialty diagnostics utilizing the s-KL protein and will pursue other medical product development and commercial opportunities of interest Exclusive, worldwide intell...

1 year ago - GlobeNewsWire